Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 27

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
30, 2025, our management,
with the participation of our President and Chief Executive Officer and Chief Financial Officer, concluded that, as of such date, our
disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no significant changes to our internal
control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recently
completed quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 21 

PART II - OTHER INFORMATION 

    Item 1.
    Legal Proceedings

Information pertaining to legal proceedings is provided
in Note 9, Commitments and Contingencies, to the unaudited condensed consolidated financial statements and is incorporated by reference
herein.

    Item 1A.
    Risk Factors

There have been no material changes to those risk factors described in
our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on April 15, 2025 under the heading “Risk
Factors”.

    Item 3.
    Defaults Upon Senior Securities

None.

    Item 4.
    Mine Safety Disclosures

Not applicable.

    Item 5.
    Other Information

Mr. Lytle resigned as EVP, Chief Financial Officer
and from the Board of Directors of the Company on August 15, 2025. Mr. Lytle’s resignation was not the result of any disagreement
with either the Board of Directors or management of the Company. Mr. Steven King, President and CEO, assumed the role of Principal Financial
Officer and Principal Accounting Officer.

Dr. Garnick resigned from the Board of Directors
of the Company and any committees of the Board of Directors effective August 15, 2025. The resignation was not the result of any disagreement
with either the Board of Directors or management of the Company.

Dr. Baffi resigned from the Board of Directors
of the Company and any committees of the Board of Directors effective August 18, 2025. The resignation was not the result of any disagreement
with either the Board of Directors or management of the Company.

During the quarter ended June 30, 2025, no director
or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in
Item 408(a) of Regulation